ReviewCNS drugs2014
Osteoporosis and multiple sclerosis: risk factors, pathophysiology, and therapeutic interventions.
Review in CNS drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Medication and bone health in multiple sclerosis: A systematic review and meta-analysis.Journal of managed care & specialty pharmacy · 2023Pooled it
- Clinical guidelines for the prevention and treatment of osteoporosis: summary statements and recommendations from the Italian Society for Orthopaedics and Traumatology.Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology · 2017Guideline
- High-intensity interval training improves bone remodeling, lipid profile, and physical function in multiple sclerosis patients.Scientific reports · 2024Trial
- Polypharmacy in outpatients with relapsing-remitting multiple sclerosis: A single-center study.PloS one · 2019Trial
- High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial.BMC neurology · 2017Trial
- Women's musculoskeletal health: insights from the 2024 National Academies of Sciences, Engineering, and Medicine report on chronic conditions.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2026Review
- Multiple Sclerosis in Women: Impact of Different Life Stages on Treatment Decisions.CNS drugs · 2026Review
- Bone Mineral Density Loss in Relapsing-remitting Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Matched Case-control Study.International journal of preventive medicine · 2026Article
- Potential ofChinese herbal medicines · 2025Review
- Prevalence of osteoporosis in chronic diseases: an umbrella review of 283 observational studies from 13 systematic reviews.BMC rheumatology · 2025Article
- Article
- Effectiveness of various diet patterns among patients with multiple sclerosis.Postepy psychiatrii neurologii · 2023Review
- Osteoporosis management and secondary fragility fracture rates in patients with multiple sclerosis: a matched cohort study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022Article
- Objectively assessed physiological, physical, and cognitive function along with patient-reported outcomes during the first 2 years of Alemtuzumab treatment in multiple sclerosis: a prospective observational study.Journal of neurology · 2022Observational
- Propionic acid beneficially modifies osteoporosis biomarkers in patients with multiple sclerosis.Therapeutic advances in neurological disorders · 2022Article
- Personalized dietary advices provided by a dietitian increase calcium intake in outpatients with multiple sclerosis-Results from a randomized, controlled, single-blind trial.Frontiers in nutrition · 2022Article
- Change and onset-type differences in the prevalence of comorbidities in people with multiple sclerosis.Journal of neurology · 2021Article
- Factors influencing peak bone mass gain.Frontiers of medicine · 2021Review
- Article
- Melatonin and Multiple Sclerosis: From Plausible Neuropharmacological Mechanisms of Action to Experimental and Clinical Evidence.Clinical drug investigation · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a chronic inflammatory-demyelinating disease of the nervous system. There has been mounting evidence showing that MS is associated with increased risk of osteoporosis and fractures. The development of osteoporosis in MS patients can be related to the cumulative effects of various factors. This review summarizes the common risk factors and physiologic pathways that play a role in development of osteoporosis in MS patients. Physical inactivity and reduced mechanical load on the bones (offsetting gravity) is likely the major contributing factor for osteoporosis in MS. Additional possible factors leading to reduced bone mass are low vitamin D levels, and use of medications such as glucocorticoids and anticonvulsants. The role of the inflammatory processes related to the underlying disease is considered in the context of the complex bone metabolism. The known effect of different MS disease-modifying therapies on bone health is limited. An algorithm for diagnosis and management of osteoporosis in MS is proposed.
Indexed as
Identifiers
24871932What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.